RT Journal Article
SR Electronic
T1 ARTIFICIAL INTELLIGENCE TOOLS FOR EFFECTIVE MONITORING OF POPULATION AT DISTANCE DURING COVID-19 PANDEMIC. RESULTS FROM AN ITALIAN PILOT FEASIBILITY STUDY (RICOVAI-19 STUDY)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.04.22270087
DO 10.1101/2022.02.04.22270087
A1 Marco Mazzanti
A1 Aldo Salvi
A1 Stefania Giacomini
A1 Elisabetta Perazzini
A1 Cinzia Nitti
A1 Susanna Contucci
A1 Massimo D’Angelo
A1 Danilo Ballanti
A1 Domenico Ursino
A1 Matteo Marcosignori
A1 Raniero Romagnoli
A1 Marcello Tavio
A1 Andrea Giacometti
A1 Serena Tomassetti
A1 Riccardo Bonazzi
A1 Matteo Maccioni
A1 Lina Zuccatosta
A1 RICOVAI-19 Study
YR 2022
UL http://medrxiv.org/content/early/2022/02/06/2022.02.04.22270087.abstract
AB In order to reduce the burden on healthcare systems and in particular to support an appropriate way to the Emergency Department (ED) access, home tele-monitoring patients was strongly recommended during the COVID-19 pandemic. Furthermore, paper from numerous groups has shown the potential of using data from wearable devices to characterize each individual’s unique baseline, identify deviations from that baseline suggestive of a viral infection, and to aggregate that data to better inform population surveillance trends. However, no evidence about usage of Artificial Intelligence (AI) applicatives on digitally data collected from patients and doctors exists. With a growing global population of connected wearable users, this could potentially help to improve the earlier diagnosis and management of infectious individuals and improving timeliness and precision of tracking infectious disease outbreaks.During the study RICOVAI-19 (RICOVero ospedaliero con strumenti di Artificial Intelligence nei pazienti con COVid-19) performed in the Marche Region, Italy, we evaluated 129 subjects monitored at home in a six-months period between March 22, 2021 and October 22, 2021. During the monitoring, personal on demand health technologies were used to collect clinical and vital data in order to feed the database and the machine learning engine. The AI output resulted in a clinical stability index (CSI) which enables the system to deliver suggestions to the population and doctors about how intervene.Results showed the beneficial influence of CSI for predicting clinical classes of subjects and identifying who of them need to be admitted at ED. The same pattern of results was confirming the alert included in the decision support system in order to request further testing or clinical information in some cases.In conclusion, our study does support a high impact of AI tools on COVID-19 outcomes to fight this pandemic by driving new approaches to public awareness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comitato Etico Regionale delle Marche - Azienda Ospedaliero-Universitaria "Ospedali Riuniti", Via Conca, 71 - 60126 Torrette di Ancona, Italy (President: Prof Paolo Pelaia) - Session Date Decision made: Ethical Approval given on March 4, 2021 N. 2021-30.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript